Fase I studies bij diverse tumoren

Op deze pagina


There are currently no planned studies in our center.


BI 1403-0001

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors

BI 1403-0002

A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 With BI 754091(Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors

BI 1403-0008 BRIGHTLINE-1

A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma


An open label, multicenter, dose escalation and extension, phase Ia/Ib study to evaluate safety, pharmacokinetics, and therapeutic activity of RO7284755, a PD-1 targeted IL-2 variant (IL-2v) immunocytokine, alone or in combination with atezolizumab in participants with advanced and/or metastatic solid tumors


Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts


A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)


A Phase I Multicentre, Open-label, Dose Escalation Study to Determine the Safety and Preliminary Efficacy of MBS8(1V270) Administered Intravenously to Cancer Patients With Advanced Solid Tumours


A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors


A Phase IA/B, Open-Label, Multicenter Study Evaluating Safety, Pharmacokinetics, And Preliminary Clinical Activity Of Ro7276389 Alone And In Combination With Cobimetinib In Participants With Braf-V600 Mutation-Positive Advanced Solid Tumor And Participants With Braf-V600 Mutation-Positive Melanoma With Central Nervous System Metastases



A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors


A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL-15/sIL-15Rα)) in Combination With Spartalizumab in Patients With Check Point Inhibitor (CPI) Relapsed Advanced Solid Tumors and Lymphoma.


An Open-Label, Multicenter, Dose-Escalation, Phase I Study To Evaluate Safety, Pharmacokinetics, And Preliminary Anti-Tumor Activity Of RO7444973 In Participants With Advanced And/Or Metastatic Mage A4-Positive, Solid Tumors


An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (Il-2v) Targeting Fibroblast Activation Protein-Α (Fap), In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma


An open-label, phase Ia/Ib dose finding study with BI 894999 oral administered once a day in patients with advanced solid tumors, with repeated administration in patients with clinical benefit


A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)


An open-label, multicenter, phase 1 study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7293583, a TYRP1-Targeting CD3 T-Cell Engager, in participants with metastatic melanoma

COSMIC-021 XL184-021

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

JAVELIN EMR 100070-001

A phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

IDH305 CIDH305X210

A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

IVIVC D0816C00024

A Phase 1, Randomised, Open-label, 4-Period Crossover Study to Develop an In Vitro-In Vivo Correlation for Olaparib Tablets in Subjects With Solid Tumor

LAG525 CLAG525X2101C

Open label multicenter phase I/II study of the safety and efficacy of LAG525 single-agent and in combination with PDR001 administered to patients with advanced malignancies


A phase I/II open-label, safety, pharmacokinetic and preliminary efficacy study of Cripec docetaxel in patients with solid tumors

PD1-Fc-OX40L SL01-DEL-101

Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas

PIVOT-02 NKTR 16-214-02

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies


An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments

SERVIER 001 CL1-81694-001

Phase I dose-escalation study of S81694 administered intravenously in adult patients with advanced/metastatic solid tumours

SERVIER 003 CL1-81694-003

Phase I/II Trial of S 81694 Administered Intravenously in Combination With Paclitaxel to Evaluate the Safety, Pharmacokinetic and Efficacy in Metastatic Breast Cancer


A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer


A Phase 1/1b First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With REGN2810 in Adult Patients With Advanced Solid Tumors


A Phase 1 First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR441000 Administered Intratumorally as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors


First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors

Laatste aanpassing: 21 maart 2023